Page 14 - Human Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Despite COVID-19, pharma R&D funding at all-time high: IQVIA According to the clinical research solutions firm, disruptions due to the pandemic did not stop the industry from fueling R&D at unprecedented levels. The IQVIA Institute for Human Data Science has released its latest industry latest report, Global Trends in R&D: Overview Through 2020. According to the findings, research and development funding maintained historically high levels, thanks to new funding sources, strategic transactions, and other activity. Murray Aitken, executive director of the IQVIA Inst...

Print this article Democratic legislation aimed at prescription drugs could sacrifice future savings in healthcare to reduce costs in the short term. House Democrats have proposed HR 3, a bill that would require the federal government to negotiate prices with drug manufacturers. The negotiated price of a drug could not exceed 120% of the average price of that drug in countries where costs are lower, including Australia, Canada, France, Germany, Japan, and the United Kingdom. But that could reduce future drug innovation. The Congressional Budget Office estimated in 2019 that HR 3 would save M...

Google to release new AI tool to identify skin conditions Google to release new AI tool to identify skin conditions Getty Images Google plans to release a new tool later this year that will use artificial intelligence to help users identify problems with their skin, hair and nails, the company said Tuesday during its annual developer conference. The innovation will compete against one of the most lucrative specialties in the industry. "As a doctor, I often see patients when it's too late," said Dr. Peggy Bui, the product lead and an internal medicine doctor. The AI is not meant to replace a ...

Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients

, 2021 – Sandoz, a global leader in biosimilar and generic medicines, today announced that the US Supreme Court has denied its petition to review the Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi ® (etanercept-szzs) for reference medicine Enbrel ®* (etanercept). The Federal Circuit previously ruled against Sandoz in a divided decision upholding Amgen’s patents. “We are disappointed the Supreme Court decided not to review our case,” said Keren Haruvi, President of Sandoz US and Head of North America. “Today’s decision means Erelzi, a more afforda...